Search
Olezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigational[A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production. … [L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia.
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaSynonyms: DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))M5RU-M5C-T-T-G-T-M5C-M5C-A-G-M5C-(2'-O-(2-METHOXYETHYL), )M5RU-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHDarolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigational[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.[L10887] … Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC).
Categories: Antiandrogens, non-steroidalCyclobenzaprine
go.drugbank.com/drugs/DB00924ApprovedInvestigational[A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond. … [A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamineIvacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigationalIt is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012[L768], and by Health Canada in late 2012. … [L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein
Synonyms: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamideTiclopidine
go.drugbank.com/drugs/DB00208ApprovedTiclopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. … It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation.
Tazemetostat
go.drugbank.com/drugs/DB12887ApprovedInvestigationalTazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. … [A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476]
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.
Sparfloxacin
go.drugbank.com/drugs/DB01208ApprovedWithdrawnSparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase.
Synthetic Conjugated Estrogens, A
go.drugbank.com/drugs/DB09317ApprovedEstrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone … There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time.
Donislecel
go.drugbank.com/drugs/DB17961Approved, by not relying on exogenous and intentional insulin administration to control blood glucose. … [L47196] Donislecel was approved by the FDA on June 28, 2023, and is available under the brand name LANTIDRA from CellTrans Inc.[L47196]